AVXL stock soars 95% in three months on positive updates from the development programs of its two clinical candidates, blarcamesine and ANAVEX 3-71.
As part of the regulatory action, memantine/donepezil extended-release capsules have been granted a 180-day exclusivity in ...
New guidelines will help doctors identify patients with a common memory-loss syndrome that is often misdiagnosed as Alzheimer's disease in older adults. The diagnostic criteria for limbic-predominant ...
Women with amnestic mild cognitive impairment and early Alzheimer’s disease had lower levels of acetyl-L-carnitine and its ...
Vigil Neuroscience reported a strong safety profile and 50% sTREM2 reduction in an early-stage trial for VG-3927, potentially ...
Daddy had once been 6 feet tall and 155 pounds. Now at 5 foot 8 and just 123 pounds, he weighed less than anyone else in the ...
Acupuncture treatment on the DU channel has shown therapeutic effects for Alzheimer’s disease (AD), but the underlying mechanisms are not yet clear. The purpose of this study was to comprehensively ...
INM-901 significantly reduced pro-inflammatory cytokines associated with Alzheimer'sStatistically significant reduction in ...
Recommendations are presented for the diagnostic evaluation of patients with Alzheimer disease (AD) or AD and related dementias (ADRD).
Vigil posted positive phase 1 results for VG-3927, but competitor Alector's failure raises concerns about phase 2. Click here ...
The Florey Dementia Index (FDI) is valid for predicting the age of onset of mild cognitive impairment (MCI) and Alzheimer disease (AD).
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback